Molecular diagnostics in chronic myeloid leukemia

Bibliography

• Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56
   PubMed Web of Science ®Google Scholar
• Marin D, Milojkovic D, Olavarria E, European leukemianet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008;112:4437-44
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Melo JV, Baccarani M, Thiele J. Chronic myelogenous leukemia BCR-ABL1 positive. In: Swerdlow SH, Campo E, Harris NL, , editors, WHO classification of tumors of hematopoietic and lymphoid tissues. IARC, Lion; 2008. p. 32-7
   Google Scholar
• Zaccaria A, Valenti AM, Donti E, Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia. Haematologica 2007;92:564-5
   PubMed Web of Science ®Google Scholar
• Richebourg S, Eclache V, Perot C, Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy. Cancer Genet Cytogenet 2008;182:95-102
   PubMed Web of Science ®Google Scholar
• Schoch C, Schnittger S, Bursch S, Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002;16:53-9
   PubMed Web of Science ®Google Scholar
• Chase A, Grand F, Zhang JG, Factors influencing the false positive and negative rates of BCR-ABL fluorescence in situ hybridization. Genes Chromosomes Cancer 1997;18:246-53
   PubMed Web of Science ®Google Scholar
• Landstrom AP, Ketterling RP, Knudson RA, Tefferi A. Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. Leuk Lymphoma 2006;47:2055-61
   PubMed Web of Science ®Google Scholar
• Reinhold U, Hennig E, Leiblein S, FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib. Leukemia 2003;17:1925-9
   PubMed Web of Science ®Google Scholar
• Huntly BJP, Guilhot F, Reid AG, Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003;102:2205-12
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J, Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European leukemianet. Blood 2006;108:1809-20
   PubMed Web of Science ®Google Scholar
• Kim DH, Popradi G, Sriharsha L, No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. Cancer 2008;113:772-781
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Talpaz M, Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005;105:2281-6
   PubMed Web of Science ®Google Scholar
• Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994;8:186-9
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, van der Velden VH, Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against cancer program. Leukemia 2003;17:2318-57
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien SG, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
   Google Scholar
• Bumm T, Muller C, Al-Ali HK, Emergence of clonal cytogenetic abnormalities in PH-negative cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003;101:1941-9
   PubMed Web of Science ®Google Scholar
• Deininger MW, Cortes J, Paquette R, The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer 2007;110:1509-19
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Moore S, Hughes TP. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia 2006;20:664-70
   PubMed Web of Science ®Google Scholar
• Buno I, Wyatt WA, Zinsmeister AR, A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood 1998;92:2315-21
   PubMed Web of Science ®Google Scholar
• Marktel S, Marin D, Foot N, Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica 2003;88:260-7
   PubMed Web of Science ®Google Scholar
• Hughes TP, Kaeda J, Branford SRZ, Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New Engl J Med 2003;349:1423-32
   PubMed Web of Science ®Google Scholar
• Ma W, Tseng R, Gorre M, Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. Haematologica 2007;92(2):170-5
   PubMed Web of Science ®Google Scholar
• Branford S, Fletcher L, Cross NC, Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008;112:3330-8
   PubMed Web of Science ®Google Scholar
• Hughes T, Deininger M, Hochhaus A, Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37
   PubMed Web of Science ®Google Scholar
• Hughes T, Hochhaus A, Branford S, Reduction of BCR-ABL transcript levels at 6, 12 and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 mo: an analysis from the international randomized study of interferon versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) [abstract]. Blood 2008;112:129-30
   Web of Science ®Google Scholar
• Branford S, Rudzki Z, Parkinson I, Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926-32
   PubMed Web of Science ®Google Scholar
• Press RD, Willis SG, Laudadio J, Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 2008;112:1108
   Google Scholar
• Marin D, Khorashad JS, Foroni L, Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? Br J Haematol 2009;145:373-5
   PubMed Web of Science ®Google Scholar
• Press RD, Galderisi C, Yang R, A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007;13:6136-43
   PubMed Web of Science ®Google Scholar
• Radich JP, Gehly G, Gooley T, Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronich myeloid leukemia: results and implications in 346 patients. Blood 1995;85 (9):2632-8
   PubMed Web of Science ®Google Scholar
• Radich JP, Gooley T, Bryant E, The significance of bcr-abl molecular detection in chronic myeloid leukemia patients ‘late,’ 18 months or more after transplantation. Blood 2001;98:1701-7
   PubMed Web of Science ®Google Scholar
• Lange T, Bumm T, Mueller M, Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation. Leukemia 2005;19:1262-5
   PubMed Web of Science ®Google Scholar
• Lange T, Deininger M, Brand R, BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning. Leukemia 2004;18:1468-75
   PubMed Web of Science ®Google Scholar
• Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-29
   PubMed Web of Science ®Google Scholar
• Apperley JF. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1116-28
   PubMed Web of Science ®Google Scholar
• Jabbour E, Jones D, Kantarjian HM, Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009;114:2037-43
   Google Scholar
• Hochhaus A, Kim DW, Martinelli G, Nilotinib efficacy according to beseline BCR-ABL mutations in patients with Imatinib-resistant CML in CP [abstract]. Blood 2008;112:1103
   PubMedGoogle Scholar
• Müller MC, Hanfstein B, Erben P, Molecular response to first line imatinib therapy is predictive for long term event free survival in patients with chronic phase CML - An Interim analysis of the randomized german CML study IV [abstract]. Blood 2008;112:333
   Google Scholar
• Ernst T, Hoffmann J, Erben P, ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2008;93:1389-93
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Gunby RH, Piazza R, Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet 2003;4:75-85
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin AS, Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-6
   PubMed Web of Science ®Google Scholar
• Deininger MW, McGreevey L, Willis S, Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia 2004;18:864-71
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Amabile M, Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib. Clin Chem 2004;50:1205-13
   PubMed Web of Science ®Google Scholar
• Ernst T, Erben P, Muller MC, Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008;93:186-92
   PubMed Web of Science ®Google Scholar
• Ernst T, Gruber FX, Pelz-Ackermann O, A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. Haematologica 2009;94:1227-35
   Google Scholar
• Khorashad JS, Anand M, Marin D, The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006;20:658-63
   PubMed Web of Science ®Google Scholar
• Willis SG, Lange T, Demehri S, High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005;106:2128-37
   PubMed Web of Science ®Google Scholar
• Oehler VG, Qin J, Ramakrishnan R, Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia 2009;23:396-9
   PubMed Web of Science ®Google Scholar
• Gruber FX, Lamark T, Anonli A, Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia 2005;19:2159-65
   PubMed Web of Science ®Google Scholar
• Pelz-Ackermann O, Cross M, Pfeifer H, Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR. Leukemia 2008;22:2288-91
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A, Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374-9
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M, Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303-9
   Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N, Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109:5143-50
   PubMed Web of Science ®Google Scholar
• Guilhot F, Apperley J, Kim DW, Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143-50
   PubMed Web of Science ®Google Scholar
• Cortes J, Rousselot P, Kim DW, Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109:3207-13
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim DW, Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-12
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242-9
   PubMed Web of Science ®Google Scholar
• Larson RA, Druker BJ, Guilhot F, Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022-8
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P, Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007;110:4064-72
   PubMed Web of Science ®Google Scholar
• Oehler VG, Guthrie KA, Cummings CL, The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 2009;114:3299-308
   PubMed Web of Science ®Google Scholar
• Lange T, Günther C, Köhler T, High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood 2003;101:2152-5
   PubMed Web of Science ®Google Scholar